Our data identified METTL3-m6A-CDCP1 axis as a downstream target during chemical-induced transformation of uroepithelial cells; therefore, we evaluated the clinical relevance of METTL3-m6A-CDCP1 oncogenic signaling axis in bladder cancer with patient samples. This evidence concerns the gene CDCP1 and urinary bladder cancer.